JPAD-Journal of Prevention of Alzheimers Disease

Papers
(The H4-Index of JPAD-Journal of Prevention of Alzheimers Disease is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats436
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217236
Ten Years after the National Alzheimer's Plan: Dementia Remains a Hidden Syndrome in France227
Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia207
Neuroprotective Effects of IVIG against Alzheimer's Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice98
Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations79
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data68
The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort50
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation48
On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use47
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease43
‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings38
Effects of Non-Invasive Brain Stimulation on Alzheimer's Disease35
Association between Comorbidity Indices and Functional Autonomy in Individuals with Cognitive Impairment: A Systematic Review33
Informal care for people with dementia in Europe33
Disparities in out-of-pocket costs for disease-modifying therapy under Japan's universal health insurance system32
Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias28
Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease24
The Shape Trail Test Is Sensitive in Differentiating Older Adults with Mild Cognitive Impairment: A Culture-neutral Five-minute Test23
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment23
Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration22
0.12335515022278